149 related articles for article (PubMed ID: 29631670)
1. Tumor Targeting with Small Molecule-Drug Conjugates (SMDCs) - Can They be Better than ADCs?
Altmann KH
Chimia (Aarau); 2018 Mar; 72(3):154-155. PubMed ID: 29631670
[No Abstract] [Full Text] [Related]
2. Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma.
Cazzamalli S; Corso AD; Neri D
J Control Release; 2017 Jan; 246():39-45. PubMed ID: 27890855
[TBL] [Abstract][Full Text] [Related]
3. Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis.
Cazzamalli S; Dal Corso A; Widmayer F; Neri D
J Am Chem Soc; 2018 Feb; 140(5):1617-1621. PubMed ID: 29342352
[TBL] [Abstract][Full Text] [Related]
4. Development of a Small Molecule Tubulysin B Conjugate for Treatment of Carbonic Anhydrase IX Receptor Expressing Cancers.
Marks IS; Gardeen SS; Kurdziel SJ; Nicolaou ST; Woods JE; Kularatne SA; Low PS
Mol Pharm; 2018 Jun; 15(6):2289-2296. PubMed ID: 29715036
[TBL] [Abstract][Full Text] [Related]
5. Targeting carbonic anhydrase IX with small organic ligands.
Wichert M; Krall N
Curr Opin Chem Biol; 2015 Jun; 26():48-54. PubMed ID: 25721398
[TBL] [Abstract][Full Text] [Related]
6. Effect of attachment site on stability of cleavable antibody drug conjugates.
Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Loo C; Krimm S; Bolton G; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A
Bioconjug Chem; 2015 Apr; 26(4):650-9. PubMed ID: 25643134
[TBL] [Abstract][Full Text] [Related]
7. Sequence-Defined Oligoamide Drug Conjugates of Pretubulysin and Methotrexate for Folate Receptor Targeted Cancer Therapy.
Truebenbach I; Gorges J; Kuhn J; Kern S; Baratti E; Kazmaier U; Wagner E; Lächelt U
Macromol Biosci; 2017 Oct; 17(10):. PubMed ID: 28371444
[TBL] [Abstract][Full Text] [Related]
8. A 99mTc-Labeled Ligand of Carbonic Anhydrase IX Selectively Targets Renal Cell Carcinoma In Vivo.
Krall N; Pretto F; Mattarella M; Müller C; Neri D
J Nucl Med; 2016 Jun; 57(6):943-9. PubMed ID: 26912427
[TBL] [Abstract][Full Text] [Related]
9. Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic.
Stagg NJ; Shen BQ; Brunstein F; Li C; Kamath AV; Zhong F; Schutten M; Fine BM
Regul Toxicol Pharmacol; 2016 Dec; 82():1-13. PubMed ID: 27773754
[TBL] [Abstract][Full Text] [Related]
10. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
Beerli RR; Hell T; Merkel AS; Grawunder U
PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
[TBL] [Abstract][Full Text] [Related]
11. Dual-pharmacophore DNA-encoded chemical libraries.
Scheuermann J; Neri D
Curr Opin Chem Biol; 2015 Jun; 26():99-103. PubMed ID: 25779969
[TBL] [Abstract][Full Text] [Related]
12. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2.
Cazzamalli S; Ziffels B; Widmayer F; Murer P; Pellegrini G; Pretto F; Wulhfard S; Neri D
Clin Cancer Res; 2018 Aug; 24(15):3656-3667. PubMed ID: 29691298
[No Abstract] [Full Text] [Related]
14. In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives.
Ahlskog JK; Dumelin CE; Trüssel S; Mårlind J; Neri D
Bioorg Med Chem Lett; 2009 Aug; 19(16):4851-6. PubMed ID: 19615903
[TBL] [Abstract][Full Text] [Related]
15. A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer.
Wu Y; Zhu M; Sun B; Chen Y; Huang Y; Gai J; Li G; Li Y; Wan Y; Ma L
J Nanobiotechnology; 2024 May; 22(1):256. PubMed ID: 38755613
[TBL] [Abstract][Full Text] [Related]
16. Small molecule- and peptide-drug conjugates addressing integrins: A story of targeted cancer treatment.
Paulus J; Sewald N
J Pept Sci; 2024 Jul; 30(7):e3561. PubMed ID: 38382900
[TBL] [Abstract][Full Text] [Related]
17. Extracellular Antibody Drug Conjugates Exploiting the Proximity of Two Proteins.
Marshall DJ; Harried SS; Murphy JL; Hall CA; Shekhani MS; Pain C; Lyons CA; Chillemi A; Malavasi F; Pearce HL; Thorson JS; Prudent JR
Mol Ther; 2016 Oct; 24(10):1760-1770. PubMed ID: 27434591
[TBL] [Abstract][Full Text] [Related]
18. Targeting carbonic anhydrase IX improves the anti-cancer efficacy of mTOR inhibitors.
Faes S; Planche A; Uldry E; Santoro T; Pythoud C; Stehle JC; Horlbeck J; Letovanec I; Riggi N; Datta D; Demartines N; Dormond O
Oncotarget; 2016 Jun; 7(24):36666-36680. PubMed ID: 27153561
[TBL] [Abstract][Full Text] [Related]
19. Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer.
Bryant JL; Gieling RG; Meredith SL; Allen TJ; Walker L; Telfer BA; Supuran CT; Williams KJ; White A
Int J Cancer; 2018 Jan; 142(1):191-201. PubMed ID: 28905987
[TBL] [Abstract][Full Text] [Related]
20. Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope.
Yamaguchi A; Anami Y; Ha SYY; Roeder TJ; Xiong W; Lee J; Ueno NT; Zhang N; An Z; Tsuchikama K
Bioorg Med Chem; 2021 Feb; 32():116013. PubMed ID: 33482584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
